Health Economics›Colorectal cancer›Perioperative therapy for oligometastatic disease

Perioperative therapy for oligometastatic disease

Colorectal cancer · 4 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 3 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
mFOLFOX6 and Cetuximab Variant #03	RAS	R 57 509	14d	~8.2 mo	~30.9 mo	~3	~R 87 490 PFS proxy · indirect	4
FOLFIRI and Cetuximab Variant #01	RAS	R 57 190	14d	~8.9 mo	~23.5 mo	~3	~R 86 532 PFS proxy · indirect	7
mFOLFOX6 Variant #02	RAS	R 2 617	14d	22.2 mo	—	6	R 15 700 PFS proxy	1
FOLFIRI Variant #05	RAS	R 2 314	14d	—	15.0 mo	5	R 11 572 PFS proxy	—

4 of 4 regimens shown